Cargando…

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study

OBJECTIVE: To evaluate the pharmacokinetics of prucalopride in individuals with renal impairment (RI). METHODS: This open-label Phase I study (ClinicalTrials.gov identifier: NCT01674192) enrolled men and women aged 18–75 years who were classified by renal function: normal renal function (creatinine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, William B, Mannaert, Erik, Verhaeghe, Tom, Kerstens, René, Vandeplassche, Lieve, Van de Velde, Vera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529624/ https://www.ncbi.nlm.nih.gov/pubmed/23269861 http://dx.doi.org/10.2147/DDDT.S36142

Ejemplares similares

Effect of Prucalopride on the Pharmacokinetics of Oral Contraceptives in Healthy Women
por: Van de Velde, Vera, et al.
Publicado: (2013)

Prucalopride Improves Bowel Function and Colonic Transit Time in Patients With Chronic Constipation: An Integrated Analysis
por: Emmanuel, Anton, et al.
Publicado: (2014)

Effect of prucalopride on symptoms of chronic constipation
por: Tack, J, et al.
Publicado: (2013)

Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study
por: Mendzelevski, Boaz, et al.
Publicado: (2012)

Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study
por: Emmanuel, A V, et al.
Publicado: (2012)

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
por: Wiebe, Sabrina, et al.
Publicado: (2016)

Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating
por: Staller, Kyle, et al.
Publicado: (2022)

Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation
por: Sloots, Cornelius E. J., et al.
Publicado: (2010)

Development of a population pharmacokinetic model of prucalopride in children with functional constipation
por: van Schaick, Erno, et al.
Publicado: (2016)

Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials
por: Camilleri, Michael, et al.
Publicado: (2016)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation
por: Yiannakou, Yan, et al.
Publicado: (2015)

Effects of Single-Dose Prucalopride on Intestinal Hypomotility in Horses: Preliminary Observations
por: Laus, Fulvio, et al.
Publicado: (2017)

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
por: Kim, Seokuee, et al.
Publicado: (2014)

An Open-Label, Head to Head Comparison Study between Prucalopride and Lactulose for Clozapine Induced Constipation in Patients with Treatment Resistant Schizophrenia
por: Damodaran, Ishwary, et al.
Publicado: (2020)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
por: Tayo, Bola, et al.
Publicado: (2019)

Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study
por: Chattopadhyay, Niladri, et al.
Publicado: (2019)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study
por: Chen, Xinhui, et al.
Publicado: (2021)

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2022)

A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
por: Gao, Ling, et al.
Publicado: (2023)

Green microwave quantum dots as luminescent probes for quantifying prucalopride: consistency of content and application to pharmacokinetic studies
por: Salman, Baher I.
Publicado: (2023)

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study
por: Dahlke, Marion, et al.
Publicado: (2015)

The Effects of Prucalopride on Postoperative Ileus in Guinea Pigs
por: Park, Soo Jung, et al.
Publicado: (2013)

Effects of prucalopride on esophageal secondary peristalsis in humans
por: Yi, Chih-Hsun, et al.
Publicado: (2016)

An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline
por: Kovacs, Steven J., et al.
Publicado: (2020)

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
por: Li, Yan, et al.
Publicado: (2018)

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
por: Moore, Kenneth T, et al.
Publicado: (2014)

Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis
por: Yang, Tao, et al.
Publicado: (2021)

Prucalopride: the evidence for its use in the treatment of chronic constipation
por: Coremans, Georges
Publicado: (2008)

Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands
por: Nuijten, Mark J. C., et al.
Publicado: (2015)

Patient considerations in the management of chronic constipation: focus on prucalopride
por: Shin, Andrea
Publicado: (2016)

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
por: Tomkinson, Helen, et al.
Publicado: (2011)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study
por: Vigone, Barbara, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study
por: Marbury, Thomas, et al.
Publicado: (2023)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation
por: Tameez Ud Din, Asim, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nmj98dnde0ntc489jfcb462l07